ArticleInternational urology and nephrology2026
Uncovering hidden risks: metabolic and inflammatory insights in normoalbuminuric chronic kidney disease.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWhile elevated levels of albuminuria beyond 30 mg/g are linked to adverse outcomes, recent studies have revealed an increased risk of chronic kidney disease (CKD) progression and cardiovascular events within the normoalbuminuric range (urinary albumin-to-creatinine ratio, UACR < 30 mg/g). This study aims to examine metabolite levels and inflammatory markers among CKD patients in the normal albuminuria groups.
methodsWe recruited 24 patients diagnosed with CKD exhibiting normoalbuminuria from The Kidney Precision Medicine Project (KPMP). The patients were divided into two groups based on their UACR levels: 0-15 mg/g and 15-30 mg/g. Differential metabolites were identified through Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS).
resultsThe results indicated that patients with CKD and a UACR of 15-30 mg/g exhibited significant pathology, including a higher percentage of tubular atrophy and elevated levels of metabolites. These metabolites were classified into Lipids (60.0%), Amino Acids and Peptides (6.6%), Cofactors and Vitamins (6.6%), and Nucleotides (3.3%), associated with porphyrin metabolism, arginine biosynthesis, lysine degradation, and fatty acid metabolism, contrasting with CKD patients having a UACR of 0-15 mg/g. Noteworthy positive correlations were observed between caprate levels and IL-12p70, gamma-glutamylleucine and IL-10, as well as taurolithocholate and IL-10.
conclusionIn patients with CKD and normal albuminuria, there exist metabolic variances compared to those with high levels of albuminuria, and these metabolites are linked to inflammatory status. This offers a foundation for early detection and proactive measures before reaching the normal threshold in CKD.
Indexed as
Identifiers
40721549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.